Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic
Therapeutic Apheresis and Dialysis · 2023
DOI: 10.1111/1744-9987.14033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2023. Verfasst von Kan Kikuchi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Introduction
In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis patients.
Methods
Dialysis patients with confirmed SARS‐CoV‐2 during the COVID‐19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared.
Results
A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group ( p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID‐19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively).
Conclusion
Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan.
- Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
- Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
- Kidney Center, Shirasagi Hospital, Osaka, Japan.
- Nagoya Memorial Hospital, Nagoya, Japan.
- Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.
ORCID-Profile: Tadao Akizawa
Zitieren
APA
Kikuchi, K., Nangaku, M., Ryuzaki, M., Yamakawa, T., Ota, Y., Hanafusa, N., Sakai, K., Kanno, Y., Ando, R., Shinoda, T., Wakino, S., Nakamoto, H., Takemoto, Y., Akizawa, T., & COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro… (2023). Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14033
Vancouver
Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Ota Y, Hanafusa N, et al. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic. Therapeutic Apheresis and Dialysis. 2023. doi:10.1111/1744-9987.14033
BibTeX
@article{Kikuchi2023,
author = {Kikuchi, Kan and Nangaku, Masaomi and Ryuzaki, Munekazu and Yamakawa, Tomoyuki and Ota, Yoshihiro and Hanafusa, Norio and Sakai, Ken and Kanno, Yoshihiko and Ando, Ryoichi and Shinoda, Toshio and Wakino, Shu and Nakamoto, Hidetomo and Takemoto, Yoshiaki and Akizawa, Tadao and COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro…, COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro…},
title = {Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic},
journal = {Therapeutic Apheresis and Dialysis},
year = {2023},
doi = {10.1111/1744-9987.14033}
}
EUVIMED